Cargando…
Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease
[Figure: see text]
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886430/ https://www.ncbi.nlm.nih.gov/pubmed/36731610 http://dx.doi.org/10.1016/j.kint.2023.01.009 |
| _version_ | 1784880129495793664 |
|---|---|
| author | Naylor, Kyla L. McArthur, Eric Dixon, Stephanie N. Kwong, Jeffrey C. Thomas, Doneal Balamchi, Shabnam Blake, Peter G. Garg, Amit X. Atiquzzaman, Mohammad Hladunewich, Michelle A. Levin, Adeera Yeung, Angie Oliver, Matthew J. |
| author_facet | Naylor, Kyla L. McArthur, Eric Dixon, Stephanie N. Kwong, Jeffrey C. Thomas, Doneal Balamchi, Shabnam Blake, Peter G. Garg, Amit X. Atiquzzaman, Mohammad Hladunewich, Michelle A. Levin, Adeera Yeung, Angie Oliver, Matthew J. |
| author_sort | Naylor, Kyla L. |
| collection | PubMed |
| description | [Figure: see text] |
| format | Online Article Text |
| id | pubmed-9886430 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Published by Elsevier, Inc., on behalf of the International Society of Nephrology. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98864302023-01-31 Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease Naylor, Kyla L. McArthur, Eric Dixon, Stephanie N. Kwong, Jeffrey C. Thomas, Doneal Balamchi, Shabnam Blake, Peter G. Garg, Amit X. Atiquzzaman, Mohammad Hladunewich, Michelle A. Levin, Adeera Yeung, Angie Oliver, Matthew J. Kidney Int Research Letter [Figure: see text] Published by Elsevier, Inc., on behalf of the International Society of Nephrology. 2023-04 2023-01-31 /pmc/articles/PMC9886430/ /pubmed/36731610 http://dx.doi.org/10.1016/j.kint.2023.01.009 Text en © 2023 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Research Letter Naylor, Kyla L. McArthur, Eric Dixon, Stephanie N. Kwong, Jeffrey C. Thomas, Doneal Balamchi, Shabnam Blake, Peter G. Garg, Amit X. Atiquzzaman, Mohammad Hladunewich, Michelle A. Levin, Adeera Yeung, Angie Oliver, Matthew J. Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title | Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title_full | Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title_fullStr | Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title_full_unstemmed | Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title_short | Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease |
| title_sort | impact of study design on vaccine effectiveness estimates of 2 mrna covid-19 vaccine doses in patients with stage 5 chronic kidney disease |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886430/ https://www.ncbi.nlm.nih.gov/pubmed/36731610 http://dx.doi.org/10.1016/j.kint.2023.01.009 |
| work_keys_str_mv | AT naylorkylal impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT mcarthureric impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT dixonstephanien impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT kwongjeffreyc impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT thomasdoneal impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT balamchishabnam impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT blakepeterg impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT gargamitx impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT atiquzzamanmohammad impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT hladunewichmichellea impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT levinadeera impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT yeungangie impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease AT olivermatthewj impactofstudydesignonvaccineeffectivenessestimatesof2mrnacovid19vaccinedosesinpatientswithstage5chronickidneydisease |